Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation‑positive non‑small cell lung cancer, receiving treatment with gefitinib or erlotinib

Inomata,Minehiko; Hayashi,Ryuji; Tanaka,Hiroaki; Shimokawa,Kazuki; Tokui,Kotaro; Taka,Chihiro; Okazawa,Seisuke; Kambara,Kenta; Ichikawa,Tomomi; Yamada,Toru; Miwa,Toshiro; Kashii,Tatsuhiko; Matsui,Shoko; Tobe,Kazuyuki

doi:10.3892/mco.2016.779

May-2016 Volume 4 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2016 Volume 4 Issue 5

Full Size Image

Article

Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation‑positive non‑small cell lung cancer, receiving treatment with gefitinib or erlotinib

Authors:
- Minehiko Inomata
- Ryuji Hayashi
- Hiroaki Tanaka
- Kazuki Shimokawa
- Kotaro Tokui
- Chihiro Taka
- Seisuke Okazawa
- Kenta Kambara
- Tomomi Ichikawa
- Toru Yamada
- Toshiro Miwa
- Tatsuhiko Kashii
- Shoko Matsui
- Kazuyuki Tobe
View Affiliations / Copyright

Affiliations: First Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930‑0194, Japan, Department of Medical Oncology, Toyama University Hospital, Toyama 930‑0194, Japan, Health Administration Center, University of Toyama, Toyama 930‑0194, Japan
Pages: 774-778
|
Published online on: February 16, 2016

https://doi.org/10.3892/mco.2016.779
Expand metrics +

Abstract

Treatment with epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has been shown to prolong survival in patients with EGFR mutation‑positive non‑small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation‑positive NSCLC receiving treatment with EGFR‑TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR‑TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression‑free survival (6.2 vs. 13.2 months; P<0.01) and overall survival (10.5 vs. 36.1 months; P<0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression‑free survival (P=0.05) and overall survival (P<0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation‑positive NSCLC receiving treatment with EGFR‑TKIs. Close observation is required in EGFR mutation‑positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR‑TKIs.

View Figures

View References

1	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
2	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
4	Inomata M, Hayashi R, Yamamoto A, Tokui K, Taka C, Okazawa S, Kambara K, Suzuki K, Ichikawa T, Yamada T, et al: Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib. Mol Clin Oncol. 3:802–806. 2015.PubMed/NCBI
5	Albain KS, Crowley JJ, LeBlanc M and Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol. 9:1618–1626. 1991.PubMed/NCBI
6	Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B and Alkis N: A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 9:e1144712014. View Article : Google Scholar : PubMed/NCBI
7	Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC and Harris AL: Tumour Angiogenesis Research Group: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 89:877–885. 2003. View Article : Google Scholar : PubMed/NCBI
8	Danner BC, Didilis VN, Wiemeyer S, Stojanovic T, Kitz J, Emmert A, Füzesi L and Schöndube FA: Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 30:1347–1351. 2010.PubMed/NCBI
9	Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation‑positive non‑small cell lung cancer, receiving treatment with gefitinib or erlotinib

This article is mentioned in:

Abstract

Figure 1

Related Articles